Oral Supplementation of Turmeric Decreases Proteinuria, Hematuria, and Systolic Blood Pressure in Patients Suffering From Relapsing or Refractory Lupus Nephritis: A Randomized and Placebo-controlled Study

Journal of Renal Nutrition

Volumn 22, Issue 1, 2012, Pages 50-57

  Khajehdehi, Parviz ^a   Zanjaninejad, Batol ^b   Aflaki, Elham ^b   Nazarinia, MohamadAli ^b   Azad, Fariborz ^a   Malekmakan, Leila ^a   Dehghanzadeh, Gholam Reza ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CURCUMA; DIET SUPPLEMENTATION; FEMALE; HEMATURIA; HUMAN; HYPERTENSION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PATHOPHYSIOLOGY; PHYTOTHERAPY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

ADULT; CURCUMA; CURCUMIN; DIETARY SUPPLEMENTS; FEMALE; HEMATURIA; HUMANS; HYPERTENSION; LUPUS NEPHRITIS; MALE; PHYTOTHERAPY; PLACEBOS; PROTEINURIA; RECURRENCE;

CURCUMA LONGA;

EID: 84855202033     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.03.002     Document Type: Article

References (38)

1. Jayne D., Passweg J., Marmont A., et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004, 13:168-176.
2. Aringer M., Houssiau F., Gordon C., et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology 2009, 48:1451-1454.
3. Grammer A.C., Lipsky P.E. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 2003, 5(suppl 4):S22-S27.
4. Robak E., Robak T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr Drug Targets 2009, 10:26-37.
5. Lanata C.M., Mahmood T., Fine D.M., et al. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus 2010, 19:935-940.
6. Aringer M., Graninger W.B., Steiner G., et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004, 50:316-319.
7. Kim Y.S., Ahn Y., Hong M.H., et al. Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells. J Cardiovasc Pharmacol 2007, 50:41-49.
8. Kurien B.T., D'Souza A., Scofield R.H. Heat-solubilized curry spice curcumin inhibits antibody-antigen interaction in vitro studies: a possible therapy to alleviate autoimmune disorders. Mol Nutr Food Res 2010, 54:1202-1209.
9. Hochberg M.C. Updating the American college of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
10. Weening J.J., D'Agati V.D., Appel G.B., et al. The classification of glomerulonephritis in systemic lupus nephritis revisited. Kidney Int 2004, 65:521-530.
11. Norby G.E., Lerang K., Holdaas H., et al. Lupus-nephritis-diagnosis and treatment. Tidsskr Nor Laegeforen 2010, 130:1140-1144.
12. Lao C.D., Ruffin M.T.I.V., Normolie D., et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006, 17:6-10.
13. Me Xian-Guo, Lin Long-Ze, Lian Li-Zhi, et al. Liquid chromatography-mass spectrometric analysis of curcuminods and sequitenterpenoids in turmeric (Curcuma longa). J Chromotogr A 1998, 818:127-132.
14. Bardin N., Ragot C., Sanmarco M. Clinical evaluation of a new quantitative enzyme-linked immunosorbent assay for detection of double stranded DNA autoantibodies. Ann N Y Acad Sci 2007, 1109:511-518.
15. Stevens L.A., Coresh J., Greene T., et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006, 354:2473-2483.
16. Ferraccioli G., Romano G. Renal interstitial cells, proteinuria and progression of lupus nephritis: a new frontier for old factors. Lupus 2008, 17:533-540.
17. Donaldo J.V., Hart G.M., Bergstrain E.J., et al. Prognostic determinants in lupus nephritis: a long-term clinicopathological study. Lupus 1995, 4:109-115.
18. Wikiera-Magoft, Medynska A., Zwolinska D. Prognostic factors in children with lupus nephritis. Wiad Lek 2005, 58(suppl 1):50-54.
19. Baqi N., Moazami S., Singh A., et al. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol 1996, 7:924-929.
20. Remuzzi M., Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448-1456.
21. Peterson J.C., Adler S., Burkart J.M., et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease study. Ann Intern Med 1995, 123:754-762.
22. Randomized placebo-controlled trial of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di studi Epidemiologici in Nefrologial). Lancet 1997, 349:1857-1863. The GISEN: Group.
23. Fioretto P., Sutherland D.E., Najafian S., et al. Remodeling of renal interstitial and tubular lesions in pancreas transplant. Kidney Int 2006, 69:907-912.
24. Hill G.S., Delahousse M., Nochy D., et al. Outcome of relapse in lupus nephritis: role of renal fibrosis and response of inflammation to therapy. Kidney Int 2002, 61:2176-2186.
25. Okada K., Wangpoengtrakul C., Tanaka T., et al. Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injury in mice. J Nutr 2001, 131:2090-2095.
26. Gaedeke J., Noble N.A., Border W.A. Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells. Kidney Int 2004, 66:112-120.
27. Shama S., Kulkarni S.K., Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Physiol 2006, 33:940-945.
28. Suresh Babu P., Srinivasan K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozocin diabetic rats. Mol Cell Biochem 1998, 181:87-96.
29. Marini R., Costallat L.T. Young age, at onset, renal involvement, and arterial hypertension are of adverse prognostic significance in juvenile systemic lupus erythematosus. Rev Rhum Engl Ed 1999, 66:303-309.
30. Emre S., Bilge I., Sirin A., et al. Lupus nephritis in children: prognostic significance of clinicopathological findings. Nephron 2001, 87:118-126.
31. Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italino per lo Studio della Nefrite Lupica (GISNEL). Am Kidney Dis 1992, 19:473-479.
32. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004, 43:S1-S290. National Kidney Foundation.
33. ter Borg E.J., Horst G., Hummer E.J., et al. Measurement of increases in anti-double-stranded DNA antibody levels as predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990, 33:634-643.
34. Tzioufas A.G., Manoussakis M.N., Drosos A.A., et al. Enzyme immunoassay for the detection of IgG, and IgM anti-ds DNA antibodies: clinical significance and specificity. Clin Exp Rheumatol 1987, 5:247-253.
35. Harkiss G.D., Hazelman B.L., Brown D.L. A longitudinal study of circulating immune complexes, DNA antibodies and complement in patients with systemic lupus erythematosus: an analysis of their relationship to disease activity. J Clin Lab Immunol 1979, 2:275-283.
36. Grennan D.M., Moseley A., Sloane D., et al. The significance of serial measurement of serum anti-native DNA antibodies and complement C3 and C4 components in the management of patients with systemic lupus erythematosus. Aust N Z Med 1977, 7:625-629.
37. Bardana E.J., Harbeck R.J., Hoffman A.A., et al. The prognostic and therapeutic implications of DNA:anti-DNA immune complexes in systemic lupus erythematosus (SLE). Am J Med 1975, 59:515-522.
38. Zonana-Nacach A., Salas M., Sanchez M.L., et al. Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: a 123-months prospective study. JRheumatol 1995, 22:45-49.